What Is an Amplatzer PFO Occluder and How Does It Work?

The Amplatzer PFO Occluder is a catheter-delivered, double-disc device made of nitinol (a nickel-titanium alloy) mesh designed to seal a patent foramen ovale, the small flap-like opening between the heart’s upper chambers that persists in roughly one in four adults after birth. Its primary clinical role is secondary stroke prevention: closing the PFO in patients who have already had a cryptogenic stroke attributed to clots crossing through the opening. The device earned FDA approval on the strength of randomized trial data showing it roughly halves the rate of recurrent stroke compared with blood-thinning medications alone, but the story of who benefits most, what complications to expect, and what the device cannot do is more layered than that headline suggests.

Why a PFO Matters

Before birth, the foramen ovale is a necessary passage that lets oxygenated blood from the placenta bypass the lungs. It normally seals shut in the first months of life. When it doesn’t, the remaining opening usually causes no symptoms at all. Most people with a PFO never know they have one. The problem arises when a blood clot that forms in a vein, often in the legs, travels to the right side of the heart and slips through the PFO into the left side, where it can reach the brain and cause a stroke. This is called paradoxical embolism.

The risk is heightened when the PFO is accompanied by an atrial septal aneurysm, a floppy, exaggerated bulging of the tissue between the upper chambers. A meta-analysis found that PFO patients with an atrial septal aneurysm had roughly three and a half times the odds of cryptogenic stroke compared with PFO patients without one.¹ That combination, a PFO plus aneurysm, is one of the anatomic features that tips the clinical balance toward closure rather than medication alone.

How the Device Gets Placed

The implant procedure is done in a catheterization lab, not an operating room. A catheter is threaded from a vein in the groin up to the heart, guided across the PFO, and the two discs of the Amplatzer device are deployed on either side of the septum, sandwiching the tissue between them. The whole process typically takes about half an hour.

Imaging guidance during the procedure has evolved. Traditionally, transesophageal echocardiography (TEE) was used, which requires the patient to be sedated or under general anesthesia because the probe sits in the esophagus. A newer alternative, intracardiac echocardiography (ICE), places a small ultrasound catheter directly inside the heart through the same venous access. ICE eliminates the need for general anesthesia and cuts fluoroscopy time, meaning less radiation exposure. One study comparing the two approaches found that fluoroscopy time averaged about six minutes with ICE versus nearly ten minutes with TEE.² ICE also provides real-time views of the device discs as they unfold and seat against the septum.³

After implantation, patients are typically placed on dual antiplatelet therapy, aspirin plus clopidogrel, for about six months to prevent clots from forming on the device surface while the body’s tissue grows over it.⁴ Most patients switch to aspirin alone after that period.

The Stroke Prevention Evidence

The pivotal trial for the Amplatzer PFO Occluder was RESPECT, a large randomized trial comparing device closure to medical therapy in patients who had already suffered a cryptogenic stroke. Early results were underwhelming, but with longer follow-up (a median of about six years), the picture clarified. Patients randomized to PFO closure had a recurrent ischemic stroke rate of about 0.58 events per 100 patient-years, compared with 1.07 per 100 patient-years in the medical-therapy group, a roughly 45% relative reduction in risk.⁵ For strokes of undetermined cause specifically, the benefit was even more pronounced, with closure reducing the hazard by about 60%.⁶

A meta-analysis pooling six randomized trials and over 3,500 patients reinforced these findings. It reported that the stroke-prevention benefit of PFO closure starts to emerge after about one year and persists over time, with an overall hazard ratio of about 0.25 to 0.28 compared with antithrombotic drugs alone and a number needed to treat of roughly 11 over a median follow-up of about three and a half years.⁷ That one-year lag is worth knowing about: in the early months after implantation, the device has not yet provided a statistical edge over medication, likely because tissue coverage of the device and the overall stroke-reduction benefit both take time to materialize.

Atrial Fibrillation After Closure

The most talked-about complication of PFO closure is new-onset atrial fibrillation (AF). This irregular heart rhythm crops up in a small but real fraction of patients. A meta-analysis of observational studies and clinical trials estimated the rate at about 3.7 per 100 patient-years of follow-up, but with a striking time pattern: the risk is heavily concentrated in the first 45 days after the procedure (about 27 per 100 patient-years) and drops sharply afterward (roughly 1.3 per 100 patient-years).⁸ Peak incidence lands around two weeks after the procedure.⁹

Why it happens is not entirely settled, but the leading explanation is mechanical irritation. A foreign body pressing against the atrial septum provokes local inflammation that can trigger abnormal electrical signals. As the heart tissue grows over the device and inflammation subsides, the arrhythmia usually resolves. Older patients appear to be at higher risk, which makes sense given that age-related changes to the atrial tissue make it more susceptible to fibrillation in the first place.¹⁰

Device choice appears to matter here. A systematic review comparing AF rates across randomized trials found that the Amplatzer device was associated with an AF rate of about 4% in the closure arm versus roughly 1.5% in the medical arm. The Gore Cardioform Septal Occluder, a competing device, showed a higher AF rate of about 6.6% versus 0.4% in its respective medical arm.¹¹ The interaction between the two devices didn’t reach statistical significance, so a definitive claim that one is safer isn’t justified, but the trend favors Amplatzer on this particular metric.

Residual Shunting and When the Seal Isn’t Perfect

Not every PFO closure results in a completely sealed septum. Some patients retain a small residual shunt, detectable by bubble contrast studies, after the device is in place. One study of patients who received the Amplatzer PFO Occluder found a residual shunt in about 19% at six months, though most were trivial in size.¹² Another study using transcranial Doppler found clinically significant residual shunting in about 22% at three months but only 14% at twelve months, suggesting the shunt rate continues to improve as endothelialization progresses.¹³

Anatomy is the biggest predictor. Patients with an atrial septal aneurysm have several times the odds of residual shunting, and larger PFO dimensions independently predict persistence.¹⁴ Ironically, the same patients who are most likely to benefit from closure (those with an aneurysm who have higher stroke risk) are also the ones most likely to have a residual leak. A larger device (35 mm versus 25 mm) was also linked to higher shunt rates, probably because a bigger device is being used precisely because the anatomy is more challenging.¹⁵

A large recent registry of over 2,300 PFO closures found that any-grade residual shunting occurred in about 9% of patients after double-disc device implantation. When a shunt did persist, percutaneous retreatment with a second device succeeded in closing it in roughly 89% of cases.¹⁶ So a residual leak is not necessarily a permanent problem.

How the Amplatzer Compares to Other Devices

Several competing PFO closure devices exist, and head-to-head data is limited but informative. A comparison across six different devices at a single experienced center found that effective closure rates ranged from 85% with the Amplatzer PFO Occluder to 100% with the Gore Cardioform. Atrial fibrillation rates ran in the opposite direction: about 4% with the Amplatzer PFO versus 13% with the Cardioform.¹⁷ In patients with an atrial septal aneurysm specifically, one study comparing the Gore and Amplatzer devices found similar residual shunt rates (about 4% moderate-to-severe at six months for both) and no device embolizations or recurrent strokes through one year of follow-up.¹⁸

A review of the Amplatzer device’s complications profile concluded it is either superior or not significantly different from other occluders on the metrics that matter most: new-onset atrial fibrillation and residual shunting.¹⁹ In practice, device selection often comes down to anatomy and operator preference rather than a clear winner-take-all clinical difference.

When Devices Need to Come Out

Surgical removal of an implanted PFO device is rare but not unheard of. A multicenter survey covering nearly 14,000 percutaneous PFO closures found that 38 devices, about 0.28%, required surgical explantation.²⁰ The most common reason was persistent chest pain, frequently attributed to nickel allergy from the nitinol frame. Other reasons included persistent residual shunts not fixable percutaneously, clots forming on the device, perforation, and in one case endocarditis.

Nickel sensitivity deserves a closer look because it catches some patients by surprise. Nitinol is roughly half nickel by weight. Most people tolerate it without issue, but in patients with an established nickel allergy, the device can provoke chronic inflammation, chest pain, and fatigue. One case report documented a patient who underwent explantation specifically for nickel allergy; at surgery, the septal tissue was heavily scarred and inflamed, requiring careful dissection.²¹ Pre-procedure patch testing for nickel allergy is sometimes done for patients with a history of metal sensitivity, though it isn’t universally performed.

There is also the question of how well the body covers the device over time. Ideally, a layer of endothelial cells grows over both discs within months, making the device biologically invisible. But this process can be incomplete. A striking case report described a patient who developed endocarditis on an Amplatzer septal occluder 12 years after implantation. At surgery, exposed metal wires were still visible, along with granulation tissue rather than smooth endothelial coverage.²² This is an exceptional case, not the norm, but it illustrates that the assumption of complete biologic incorporation isn’t always warranted, and lifelong attention to febrile illnesses remains reasonable for anyone with an intracardiac device.

PFO Closure and Migraine

One of the more intriguing side plots in PFO research is the link to migraine, especially migraine with aura. The leading theory is that microemboli or vasoactive substances in venous blood normally filtered out by the lungs can sneak through a PFO and trigger cortical spreading depression, the wave of neural activity believed to produce aura.²³

Randomized trials have tested whether closing the PFO reduces migraine burden. The PREMIUM trial found that PFO closure reduced headache days by about 3.4 per month versus 2.0 in a sham-control group. Complete migraine remission for a full year occurred in about 8.5% of closure patients versus 1% of controls.²⁴ A pooled analysis of device trial data involving 337 patients confirmed these patterns: closure produced a greater reduction in monthly migraine days (about 3.1 days versus 1.9) and monthly attacks (2.0 versus 1.4), and 9% of closure patients achieved complete migraine cessation compared with less than 1% of those on medication alone.²⁵

The effect is real but modest for most patients. A reduction of one extra migraine day per month over medical therapy is meaningful for severe sufferers, but PFO closure is not currently approved as a migraine treatment. Most guidelines reserve it for stroke prevention, and the migraine benefit, when it occurs, is considered a welcome secondary effect. Patients should not undergo PFO closure solely for headache relief based on current evidence.

Divers and Decompression Illness

Scuba divers with a PFO face a specific risk: nitrogen bubbles that form during ascent can cross from the venous side to the arterial side through the PFO, causing decompression sickness (DCS) that hits the brain or spinal cord rather than just the joints. A long-term follow-up study of recreational divers found that those with a PFO who did not have it closed experienced major neurological decompression events at a dramatically higher rate than those who underwent closure. Over more than five years and thousands of dives, the PFO-closure group had a rate of major DCS events comparable to divers without a PFO, while unclosed-PFO divers had a rate roughly 70 times higher.²⁶ The closure group also accumulated far fewer silent ischemic brain lesions on follow-up MRI.

For divers who have already suffered a major DCS event and want to continue diving, PFO closure is sometimes pursued to allow them to return to unrestricted diving rather than accepting conservative dive profiles for life.²⁷ Routine screening of all recreational divers for PFO remains controversial, though, because the absolute risk for any individual dive is small and most PFO-carrying divers never have a problem.

Cost-Effectiveness

An implant procedure that costs several thousand dollars (or euros) more upfront than a prescription for blood thinners naturally invites questions about value. Multiple economic analyses have found that PFO closure is cost-effective over the long term for secondary stroke prevention, largely because recurrent strokes are enormously expensive and life-altering. A U.S.-based analysis projected that over 15 years, PFO closure actually saved money compared with medical therapy alone while also improving quality-adjusted life years, making it what economists call a “dominant” strategy in the base case.²⁸ A French analysis using a ten-year horizon found that the Amplatzer device plus medical therapy resulted in better outcomes at a cost of about 46,000 euros per additional quality-adjusted life year, well within accepted cost-effectiveness thresholds in most health-care systems.²⁹

These projections hinge on the stroke-reduction benefit remaining stable over time. If the true hazard ratio for closure turns out to be closer to the upper bound of the confidence interval than the point estimate, the cost-effectiveness picture weakens considerably.³⁰ In practical terms, this means proper patient selection matters: the more confident clinicians are that a given patient’s stroke was truly caused by paradoxical embolism through the PFO, the stronger the economic and clinical case for closure.

Detecting the PFO in the First Place

You might wonder how PFOs are found before deciding on closure. The gold-standard imaging test is transesophageal echocardiography with a bubble contrast injection, but there is a less invasive screening tool: contrast-enhanced transcranial Doppler (c-TCD). This test monitors blood flow in the brain’s arteries while agitated saline (tiny bubbles) is injected into a vein. If bubbles appear in the brain’s circulation, something is letting venous blood cross to the arterial side. A systematic review and meta-analysis of c-TCD’s diagnostic accuracy reported a pooled sensitivity of about 95% and specificity around 90% for detecting PFO compared with the transesophageal echo standard.³¹ Because it is noninvasive and doesn’t require sedation, c-TCD is often used as a first-line screen, with the more detailed transesophageal study reserved for patients who test positive and are being considered for closure.